Bactiguard®

Pareto Securities' 16th Annual Healthcare Conference

16 September 2025

Christine Lind, CEO

This is Bactiguard

advanced technology to prevent **medical device related infections**

established **license partnerships** with global MedTech giants

wound management portfolio – wound healing and infection prevention

Setting the standard in infection prevention

Unmet need

Healthcare-associated infections and chronic wounds create a multi-billion cost burden

Validated technology

Products on market with global MedTech partners, supported by clinical evidence

Scalable platform

Leverageable across multiple therapeutic areas, using a licensing model

Growth drivers

EBITDA-positive with opportunities for growth in both licencing and Wound Management

High unmet medical need for infection solutions

Focus Therapeutic Areas

	Orthopedics[1-3]	Cardiology[4,5]	Neurology[6,7]	Urology[8]	Vascular access[9]
					
Application areas (examples)	*Hip & Knee Implants* *Spinal discs / Fusion cages* *Trauma Implants & hardware*	*Ventricular Assisted Device* *Pacemaker*	*Deep Brain Stimulator* *Vagus Nerve Stimulator* *Peripheral Nerve Stimulator*	*Foley Catheter*	*Central Venous Catheter* *Peripherally Inserted Central Catheter* *Midline Catheter*
Indicative infection rates	Primary **1-5%** Revisions **8-22%** Fracture related **5-40%**	CIED **1-7%** Structural heart **19-39%**	Modulators: **1-15%** Shunts: **5-13%**	CAUTI **9-21%** (>2 days)	CLABSI **2-10%** (>2 days)
Indicative mortality rates	**3-11%**	CIED **3-5%** Structural heart **5-10%**	**10-12%***	**1-4%**	**12-31%**
Addressable market	USD **39bn**	USD **10bn**	USD **9bn**	USD **5bn**	USD **11bn**

1. Masters et al. (2013); Acuña et al. (2021) 2. Gold et al. (2019); Patel et al. (2023) 3. Norris et al. (2019); Li et al. (2024) 4. Greenspon et al. (2011); Wilkoff et al. (2020); Solail Henrikson et al. (2011) 5. Mehra, Goldstein et al. (2022); Tong et al. (2015); Topkara et al. (2010) 6. Bendel et al. (2017); Ishizuka et al. (2007); Oh et al. (2002); Hasegawa et al. (2021) 7. Sagun Tuli et al. (2004) 8. CDC and Lo et al. 2014 9. Rosenthal et al. (2023); Alshahrani et al. (2023)

Advanced technology to prevent medical device related infections

Reduces microbial adhesion and biofilm formation

- **Ultra-thin noble metal coating**
- In contact with fluids, the noble metals create a **galvanic effect** due to their varying electro potentials

20+
materials coated

250M+
devices coated

100,000+
trial participants

70%
infection reduction

ZERO
adverse events related to the coating





Validated by global MedTech partners

BD (Becton, Dickinson and Company)

One of the **largest global MedTech companies** in the world

Bactiguard engages with BD across the entire value chain, from technology through go-to-market strategies

At a glance

- Revenues: **Q2 2025** 19.2 MSEK. **2024** 124.7 MSEK
- Partnership since 1990 – 245M coated Foley catheters sold
- Exclusive global license for coated Foley catheters (ex China)

ZIMMER BIOMET

A **global leader** in orthopedics – comprehensive portfolio designed to maximize mobility and improve health

ZNN Bactiguard trauma implant on market under Zimmer Biomet's Infection prevention banner



At a glance

- Revenues: **Q2 2025** 14.2 MSEK. **2024** 27.7 MSEK
- Partnership since 2019
- Agreement covers trauma implant segment

Advancing the partnership pipeline

Exclusivity partnerships and **License partnerships** announced with partner name

	Material transfer agreement	Application development partnership	Exclusivity partnership	License partnership
Orthopedics				ZIMMER BIOMET
Cardiology	✓			
Neurology				
Urology				BD, wellead
Vascular access	✓			
Other	✓			

Wound Management portfolio

Preventing infections through effective, biocompatible solutions to improve wound healing

- **Hydrocyn aqua**, an innovative wound care product enabling wound healing and preventing infection
- Effective against bacteria, fungi and spores. Non-toxic, non-stinging, no adverse events in clinical studies
- Offering also includes speciality **surgical sutures,** including for cardiovascular and eye operations

At a glance

HYDROCYN® aqua

- **Revenues:** Q2 2025 13.8 MSEK. 2024 60.9 MSEK
- **Acquired in 2020**



Total revenue driven by License partners and Wound Management growth



Source: Bactiguard Holding AB, Interim report Q2 2025, p. 4

Positive EBITDA momentum continues



Source: Bactiguard Holding AB, Interim report Q2 2025, p. 15

The new Bactiguard

The **premier partner** for leading MedTech companies

Strategic focus

License partnerships	Advance current and develop new partnerships
R&D Medical Regulatory	Continue to invest in key knowledge areas
Wound Management portfolio	Grow profitably and expand into new markets

Targets by year-end 2030

- **>10** **application areas** in either **exclusivity** or **license partnership**
- **>200** **MSEK EBITDA**
- **>600** **MSEK Revenues**

> *The most promising aspect of healthcare going forward is prevention, period.*

Doctor Richard Kuntz
BACTIGUARD BOARD MEMBER